Insider Selling: Asensus Surgical, Inc. (NYSEAMERICAN:ASXC) Director Sells 27,010 Shares of Stock
Asensus Surgical, Inc. (NYSEAMERICAN:ASXC – Get Rating) Director William N. Starling, Jr. sold 27,010 shares of the business’s stock in a transaction dated Monday, June 13th. The stock was sold at an average price of $0.40, for a total transaction of $10,804.00. Following the completion of the sale, the director now owns 13,846 shares in the company, valued at $5,538.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of Asensus Surgical stock traded down $0.03 during trading hours on Thursday, reaching $0.36. The company’s stock had a trading volume of 9,880 shares, compared to its average volume of 2,825,999. Asensus Surgical, Inc. has a one year low of $0.35 and a one year high of $3.68.
Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its stake in Asensus Surgical by 68.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 210,737 shares of the company’s stock worth $133,000 after acquiring an additional 85,487 shares in the last quarter. Ergoteles LLC purchased a new stake in shares of Asensus Surgical in the 1st quarter worth approximately $36,000. GSA Capital Partners LLP purchased a new stake in shares of Asensus Surgical in the 1st quarter worth approximately $138,000. Advisor Group Holdings Inc. lifted its position in shares of Asensus Surgical by 12.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 279,923 shares of the company’s stock worth $2,090,000 after purchasing an additional 30,676 shares during the period. Finally, Daiwa Securities Group Inc. lifted its position in shares of Asensus Surgical by 45.7% in the 1st quarter. Daiwa Securities Group Inc. now owns 95,198 shares of the company’s stock worth $60,000 after purchasing an additional 29,880 shares during the period.
About Asensus Surgical (Get Rating)
Asensus Surgical, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery.
Receive News & Ratings for Asensus Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Asensus Surgical and related companies with MarketBeat.com’s FREE daily email newsletter.